EFFICACY OF CURCUMIN IN ORAL SUBMUCOUS FIBROSIS – A RANDOMIZED CONTROLLED CLINICAL TRIAL
AbstractIntroduction: Oral submucous fibrosis (OSMF) is a potentially malignant disorder carrying a high risk of malignant transformation. A wide range of treatment modalities have been proposed for OSMF but none have proved curative or reduced the morbidity significantly. In-vitro and in-vivo studies suggested curcumin as an anticancer, antioxidant and anti-inflammatory agent. Thus based on this literature survey the study was undertaken. Aim: To evaluate the efficacy of curcumin for the treatment of clinical stage 2 OSMF patients and to compare it with patients receiving placebo drugs. Study Design and Sample Size: A randomized single blinded placebo controlled clinical trial was conducted in 100 clinical stage 2 OSMF patients with clinically and histopathologically confirmed diagnosis. Materials and Methods: 100 clinical stage 2 patients selected for the study were divided into 2 groups with 50 patients each. Group 1 patients were given placebo capsules. Group 2 patients were given curcumin capsules of 500 mg. The primary outcome measures were to note the subjective symptoms and objective parameters. These parameters were analyzed at baseline and 6th month. Patients were also evaluated histopathologically after 6 months. ANOVA, students t test and p value were utilized for statistical inferences. Results: Patients in group 2 showed statistically significant improvement in all the subjective signs and symptoms and histopathological changes with p value of < 0.001 when compared with group 1 patients. Conclusion: It is evident from the study that curcumin holds good promise in the treatment of OSMF.
Article Information
31
5277-5286
440
1189
English
IJPSR
S. A. Ara *, J. Mudda, A. Lingappa, P. Rao and S. Zakaullah
Department of Oral Medicine and Radiology, Al-Badar Rural Dental College and Hospital Gulbarga, Karnataka, India.
drarshiyazaka@gmail.com
17 April, 2018
20 June, 2018
02 July, 2018
10.13040/IJPSR.0975-8232.9(12).5277-86
01 December, 2018